You are viewing the site in preview mode

Skip to content

Advertisement

  • Poster presentation
  • Open Access

Type II NKT cells differentially regulate CD4 T cell subsets

  • 1,
  • 2,
  • 1, 1 and
  • 1
Journal for ImmunoTherapy of Cancer20142 (Suppl 3) :P233

https://doi.org/10.1186/2051-1426-2-S3-P233

  • Published:

Keywords

  • Cell Subset
  • Adaptive Immune System
  • Antigenic Stimulation
  • Tumor Immunity
  • Immune Cell Population

Natural killer T (NKT) cells lie at the interface between the innate and adaptive immune systems and are important mediators of tumor immunosurveillance. This CD1d-restricted lymphoid population recognizes lipid antigen and can rapidly produce an array of cytokines and chemokines to modulate the host immune response. In tumor immunity, two NKT cell subsets (type I and type II) have contrasting roles in which they not only distinctly impact innate and adaptive immune cell populations, but also cross-regulate one another. Type I NKT cells are usually associated with the promotion of tumor immunity whereas type II NKT cells seem to suppress it. Previous studies showed that type II NKT cells negatively impact CD8+ T cells; however, little is known about their effect on CD4+ T helper subsets. In this study, we investigated how CD4+ T cell subsets are affected by type II NKT cells activated with sulfatide, an endogenous glycolipid antigen known to activate type II NKT cells. Naïve ovalbumin (OVA) specific CD4+ T cells isolated from DO11.10 transgenic mice were either tested ex vivo, or polarized in vitro into T helper subsets (Th1, Th2 and Th17). CFSE dilution and ELISAs were used to assess CD4+ T cell proliferative and cytokine responses upon antigenic stimulation in the presence or absence of sulfatide-activated type II NKT cells. We found that activated type II NKT cells significantly inhibited proliferation of naïve CD4+ T cells. The differentiated activated/memory subsets appeared to be less susceptible to such suppression. Ongoing elucidation of these interactions and mechanisms may not only augment our understanding of CD4+ T cell regulation, but also improve our capability to utilize type II NKT cells for clinical applications.

Authors’ Affiliations

(1)
Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
(2)
Division of Target Discovery, Otsuka Maryland Medicinal Laboratory, Rockville, MD, USA

Copyright

© licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement